Abstract
The current study was designed to determine the cardiovascular effect of centrally administrated melittin, a phospholipase A2 (PLA2) activator, and the mediation of central thromboxane A2 (TXA2) and its receptors in normotensive conscious rats. Studies were performed in normotensive male Sprague Dawley rats injected intracerebroventricularly (i.c.v.) with melittin. Melittin (1.5, 3.0, 6.0 microg/5.0 microl; i.c.v.) caused dose- and time-dependent increases in mean arterial pressure (MAP) and decrease in heart rate (HR). Maximal effects were observed 5-10 min after 3.0 microg dose of melittin. In order to test the mediation of central TXA2 and its central receptors in the cardiovascular effect of melittin, the rats were pretreated with furegrelate (500.0 microg; i.c.v.), a TXA2 synthesis inhibitor, and SQ-29548 (8.0 microg; i.c.v.), a TXA2 receptor antagonist, 15 min prior to melittin (3.0 microg). Furegrelate or SQ-29548 partially inhibited the pressor effect and bradycardia elicited by melittin. In conclusion, our findings show that centrally administered melittin increases MAP and decreases HR in conscious rats. Moreover, according to our findings, central TXA2 and its receptors may in part mediate melittin-induced cardiovasc...Continue Reading
References
Apr 1, 1991·Critical Care Medicine·D L KongD S DeWitt
Dec 1, 1989·Hypertension·X P YangA G Scicli
Oct 1, 1988·The Journal of Pharmacy and Pharmacology·G R Thomas, C R Hiley
Oct 1, 1988·Prostaglandins·G K LoveladyC W Leffler
Apr 1, 1986·Endocrinology·D P BrooksJ T Crofton
Sep 1, 1985·Canadian Journal of Physiology and Pharmacology·A S AdeagboF Coceani
Mar 1, 1984·Hypertension·G R ThomasP J Privitera
Jan 1, 1982·Journal of Neurochemistry·L S Wolfe
Feb 7, 1982·Life Sciences·A L Sirén
Apr 1, 1982·Prostaglandins, Leukotrienes, and Medicine·A L Sirén
Nov 1, 1982·Acta Physiologica Scandinavica·A L Sirén
Mar 20, 1998·European Journal of Endocrinology·K YamaguchiK Watanabe
May 23, 1998·The Journal of Physiology·L R GreenM A Hanson
Aug 29, 1998·Neuroscience·Y MurakamiY Osumi
Jan 14, 1999·Neuroscience Letters·G Y MolloyR J Williams
Jun 23, 2000·European Journal of Pharmacology·K YokotaniM Hirata
May 2, 2002·Neuroscience Letters·Hideto AriumiHiro-o Kamiya
Oct 3, 2002·European Journal of Pharmacology·Yoshinori MurakamiKunihiko Yokotani
Mar 11, 2003·American Journal of Physiology. Regulatory, Integrative and Comparative Physiology·Zhi-Hua ZhangRobert B Felder
Mar 6, 2004·Pharmacology·Murat Yalcin, Vahide Savci
Jul 16, 2004·Prostaglandins, Leukotrienes, and Essential Fatty Acids·Akhlaq A Farooqui, Lloyd A Horrocks
Sep 1, 2005·Naunyn-Schmiedeberg's Archives of Pharmacology·Murat YalcinVahide Savci
Jan 13, 2006·Clinical and Experimental Pharmacology & Physiology·Murat YalcinVahide Savci
Citations
Aug 26, 2009·Clinical and Experimental Pharmacology & Physiology·Murat Yalcin, Cenk Aydin
Apr 8, 2014·Brain Research·Bora B TopuzMurat Yalcin
Jul 30, 2014·Canadian Journal of Physiology and Pharmacology·Burcin AltinbasMurat Yalcin
Feb 18, 2011·Canadian Journal of Physiology and Pharmacology·Murat Yalcin
Jan 16, 2016·Respiratory Physiology & Neurobiology·Leman Gizem ErkanMurat Yalcin
Sep 22, 2012·Prostaglandins, Leukotrienes, and Essential Fatty Acids·Burcin AltinbasMurat Yalcin
Jun 11, 2011·Prostaglandins, Leukotrienes, and Essential Fatty Acids·Murat Yalcin, Cenk Aydin
Nov 17, 2009·Prostaglandins, Leukotrienes, and Essential Fatty Acids·Murat YalcinVahide Savci
Jun 24, 2008·Prostaglandins, Leukotrienes, and Essential Fatty Acids·Cenk Aydin, Murat Yalcin
Sep 28, 2007·Neuropeptides·Murat Yalcin, Vahide Savci
Jan 16, 2007·Neuropeptides·Murat Yalcin, Melih Erturk
Apr 2, 2011·Biochemical and Biophysical Research Communications·Yi-Ru DuJun Chen
Jan 1, 2015·Autonomic Neuroscience : Basic & Clinical·Kazuo AndoShoshiro Okada
Jan 8, 2021·Brain Research·Burcin AltinbasMurat Yalcin